Decoding Clinical Biomarker Space of COVID-19: Exploring Matrix Factorization-based Feature Selection Methods

Saberi-Movahed, Farshad; Mohammadifard, Mahyar; Mehrpooya, Adel; Rezaei-Ravari, Mohammad; Berahmand, Kamal; Rostami, Mehrdad; Karami, Saeed; Najafzadeh, Mohammad; Hajinezhad, Davood; Jamshidi, Mina; Abedi, Farshid; Mohammadifard, Mahtab; Farbod, Elnaz; Safavi, Farinaz; Dorvash, Mohammadreza; Eftekhari, Mohammad; Vahedi, Shahrzad; Saberi-Movahed, Farid; Tavassoly, Iman

doi:10.1101/2021.07.07.21259699

Cited by 17 publications

(8 citation statements)

References 116 publications

(132 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The RBD has diversity among coronaviruses, hypothesized by the fact that different coronaviruses bind to different host-cell receptors upon entry. However, SARS-CoV and SARS-CoV-2 enter the host cell via the same receptor (angiotensin-converting enzyme 2, ACE2), which confirms the similarity in their RBD sequences (3,7,8).…”

Section: Sars-cov-2 Structuresupporting

confidence: 56%

A Review of Virus-Like Particle-Based SARS-CoV-2 Vaccines in Clinical Trial Phases

2022

View full text Add to dashboard Cite

: The Coronavirus disease 2019 (COVID-19) pandemic has affected more than 269 million worldwide, with more than five million deaths as of early December 2021. The main concerns in this pandemic include the asymptomatic nature of COVID-19, leading to the infection of many healthy people, the infectious nature of the pathogen, and its high spreading rate. The disease features have highlighted the importance of controlling this pandemic via vaccines. There has been a worldwide race to produce better, more protective, and efficacious vaccines. Simultaneously, different new variants of the virus are emerging. Therefore, there is a concern about the efficacy of the vaccines against new variants. The platform used for COVID-19 vaccine development needs to be flexible enough to enable the manufacturer to react suitably to new virus variants. We performed a comprehensive search in the online databases of PubMed, Scopus, Google Scholar, clinicaltrials.gov, WHO, ICTRP, and Cochrane until December 10th, 2021. There are 331 candidate vaccines in clinical development, with 194 in the preclinical stage and 137 in different clinical phases. Eleven platforms have been used for the development of COVID-19 vaccines, including inactivated/live attenuated virus, protein subunit, virus-like particle (VLP), non-replicating/replicating viral vectors (VVnr or VVr), VVr or VVnr plus antigen-presenting cell, bacterial antigen-spore expression vector, DNA, and RNA. The VLP-based vaccine platform is a safe, highly immunogenic, and flexible platform for developing vaccines. This review focuses on VLP-based vaccine platforms and explicitly discusses the six VLP-based COVID-19 vaccines in clinical trial phases.

show abstract

Section: Sars-cov-2 Structuresupporting

confidence: 56%

A Review of Virus-Like Particle-Based SARS-CoV-2 Vaccines in Clinical Trial Phases

2022

View full text Add to dashboard Cite

show abstract

“…They used data from the 2005 DARPA Grand Challenge to compare nearby surface points acquired with a laser. Bajracharya et al [ 6 ] did the same kind of work in their research. They used self-supervised training from sensors to know the near-field terrain traversability.…”

Section: Related Workmentioning

confidence: 95%

“…For example, researchers [ 3 , 4 ] used a support vector regression algorithm to predict the water parameters. Considering physical and operational factors, another group of researchers [ 5 ] engaged AI to assess pipe break rate and [ 6 ] decoding clinical biomarker space of COVID-19. Nowadays, AI is also broadly used in building the smart city [ 7 , 8 ], smart meter [ 9 , 10 ], agriculture [ 11 , 12 , 13 ], education [ 14 , 15 ], healthcare [ 16 , 17 , 18 ] and so on.…”

Section: Introductionmentioning

confidence: 99%

Delicar: A Smart Deep Learning Based Self Driving Product Delivery Car in Perspective of Bangladesh

Chy

Masum

Sayeed

et al. 2021

Sensors

View full text Add to dashboard Cite

The rapid expansion of a country’s economy is highly dependent on timely product distribution, which is hampered by terrible traffic congestion. Additional staff are also required to follow the delivery vehicle while it transports documents or records to another destination. This study proposes Delicar, a self-driving product delivery vehicle that can drive the vehicle on the road and report the current geographical location to the authority in real-time through a map. The equipped camera module captures the road image and transfers it to the computer via socket server programming. The raspberry pi sends the camera image and waits for the steering angle value. The image is fed to the pre-trained deep learning model that predicts the steering angle regarding that situation. Then the steering angle value is passed to the raspberry pi that directs the L298 motor driver which direction the wheel should follow. Based upon this direction, L298 decides either forward or left or right or backwards movement. The 3-cell 12V LiPo battery handles the power supply to the raspberry pi and L298 motor driver. A buck converter regulates a 5V 3A power supply to the raspberry pi to be working. Nvidia CNN architecture has been followed, containing nine layers including five convolution layers and three dense layers to develop the steering angle predictive model. Geoip2 (a python library) retrieves the longitude and latitude from the equipped system’s IP address to report the live geographical position to the authorities. After that, Folium is used to depict the geographical location. Moreover, the system’s infrastructure is far too low-cost and easy to install.

show abstract

“…Accordingly, these laboratory parameters should be considered most. In addition, abnormally increased levels of CRP are correlated with worse prospects and more rates of mortality in patients with COVID-19 72 . However, further studies are needed to find a reliable relationship between these common laboratory parameters and ChAdOx1 nCov-19 vaccine-induced TTS.…”

Section: Findings From the Systematic Review 321 Patient Characterist...mentioning

confidence: 99%

ChAdOx1 nCoV-19 Vaccine and Thrombosis with Thrombocytopenia Syndrome among Adults: A Systematic Review

Faghihi¹,

Mottaghi-Dastjerdi²,

Sharifzadeh³

et al. 2023

Adv Pharm Bull

View full text Add to dashboard Cite

Several vaccine-induced thrombotic thrombocytopenia syndrome (VITTS) cases have been reported after the ChAdOx1 nCov-19 vaccination. The current study systematically reviewed the reported post-ChAdOx1 nCoV-19 vaccination thrombotic thrombocytopenia cases. Their laboratory and clinical features, as well as the diagnostic and therapeutic measures, were investigated. Online databases were searched until 25 August 2021. Studies reporting post-ChAdOx1 nCov-19 vaccination TTS were included. Overall, 167 cases (21-77 years old) from 53 publications were included showing a female dominance of 1.75 times. About 85% of the cases exhibited the primary symptoms within the first two weeks post-vaccination. Headache was the most common initial symptom (>44.2%), and hemorrhage/thrombotic problems (22.46%), as well as discoordination/weakness/numbness/hemiparesis/cyanotic toes (19.6%), were the most prevalent uncommon initial symptoms. Prothrombin time (PT), D-dimers, and C-reactive protein were the most remarkable increased laboratory parameters in 50.6%, 99.1%, and 55.6% of cases, respectively. In comparison, platelet and fibrinogen were the most remarkable decreased laboratory parameters in 92.7% and 50.5% of cases, respectively. Most VITT cases presented with cerebral venous thrombosis (CVT)/cerebral venous sinus thrombosis (CVST), supraventricular tachycardia (SVT), transverse sinus/cerebral thrombosis, pulmonary embolism (PE), and cerebral hemorrhage. Anti-PF4 antibody measurement through immunoassays and functional assays were positive in 86.2% and 73% of cases, respectively. About 31% of the cases died. Early diagnosis and proper therapeutic measures are important in ChAdOx1 nCov-19 vaccine-induced VITTS patients. Therefore, experts are recommended to know the corresponding clinical and laboratory features, as well as diagnostic methods. Elucidation of the pathophysiologic mechanism of ChAdOx1 nCov-19 vaccine-induced TTS deserves further investigation.

show abstract

Decoding Clinical Biomarker Space of COVID-19: Exploring Matrix Factorization-based Feature Selection Methods

Cited by 17 publications

References 116 publications

A Review of Virus-Like Particle-Based SARS-CoV-2 Vaccines in Clinical Trial Phases

A Review of Virus-Like Particle-Based SARS-CoV-2 Vaccines in Clinical Trial Phases

Delicar: A Smart Deep Learning Based Self Driving Product Delivery Car in Perspective of Bangladesh

ChAdOx1 nCoV-19 Vaccine and Thrombosis with Thrombocytopenia Syndrome among Adults: A Systematic Review

Contact Info

Product

Resources

About